| Year |
Citation |
Score |
| 2022 |
Gonzalez MA, Olivas IM, Bencomo-Alvarez AE, Rubio AJ, Barreto-Vargas C, Lopez JL, Dang SK, Solecki JP, McCall E, Astudillo G, Velazquez VV, Schenkel K, Reffell K, Perkins M, Nguyen N, ... ... Eiring AM, et al. Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism. Clinical and Translational Medicine. 12: e1146. PMID 36536477 DOI: 10.1002/ctm2.1146 |
0.353 |
|
| 2022 |
Lara JJ, Bencomo-Alvarez AE, Gonzalez MA, Olivas IM, Young JE, Lopez JL, Velazquez VV, Glovier S, Keivan M, Rubio AJ, Dang SK, Solecki JP, Allen JC, Tapia DN, Tychhon B, ... ... Eiring AM, et al. 19S Proteasome Subunits as Oncogenes and Prognostic Biomarkers in FLT3-Mutated Acute Myeloid Leukemia (AML). International Journal of Molecular Sciences. 23. PMID 36498916 DOI: 10.3390/ijms232314586 |
0.31 |
|
| 2021 |
Zhao H, Pomicter AD, Eiring AM, Franzini A, Ahmann J, Hwang JY, Senina AV, Helton B, Iyer SM, Yan D, Khorashad JS, Zabriskie MS, Agarwal A, Redwine HM, Bowler AD, et al. MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia by Enhancing Common β Chain Cytokine Receptor Endocytosis. Blood. PMID 34780648 DOI: 10.1182/blood.2021011802 |
0.354 |
|
| 2021 |
Bencomo-Alvarez AE, Rubio AJ, Olivas IM, Gonzalez MA, Ellwood R, Fiol CR, Eide CA, Lara JJ, Barreto-Vargas C, Jave-Suarez LF, Nteliopoulos G, Reid AG, Milojkovic D, Druker BJ, Apperley J, ... ... Eiring AM, et al. Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B. Oncogene. PMID 33712704 DOI: 10.1038/s41388-021-01732-6 |
0.398 |
|
| 2020 |
Patel AB, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, Tantravahi SK, Kovacsovics TJ, Shami PJ, O'Hare T, Deininger MW. Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia. PMID 32409689 DOI: 10.1038/S41375-020-0858-1 |
0.464 |
|
| 2020 |
Than H, Pomicter AD, Yan D, Beaver LP, Eiring AM, Heaton WL, Senina A, Clair PM, Shacham S, Mason CC, Hare TO, Deininger MW. Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells. Leukemia. PMID 31980730 DOI: 10.1038/S41375-020-0708-1 |
0.404 |
|
| 2019 |
Bencomo-Alvarez AE, Rubio AJ, Gonzalez MA, Eiring AM. Energy metabolism and drug response in myeloid leukaemic stem cells. British Journal of Haematology. PMID 31236939 DOI: 10.1111/Bjh.16074 |
0.35 |
|
| 2019 |
Eiring AM, Ellwood R, Fiol CR, Hills RK, Nteliopoulos G, Reid A, Milojkovic D, Apperley J, Sorouri-Khorashad J. Abstract 3018: Mechanisms of tyrosine kinase inhibitor resistance in chronic myeloid leukemia Cancer Research. 79: 3018-3018. DOI: 10.1158/1538-7445.Am2019-3018 |
0.462 |
|
| 2018 |
Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, Wang Q, Than H, Patel AB, Heaton W, Eiring AM, Clair PM, Gantz KC, Redwine HM, Swierczek SI, et al. Nuclear-cytoplasmic transport is a therapeutic target in myelofibrosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30563936 DOI: 10.1158/1078-0432.Ccr-18-0959 |
0.376 |
|
| 2018 |
Patel AB, Pomicter AD, Yan D, Eiring AM, Franzini A, O'Hare T, Deininger MW. Combining Dasatinib and AC220 Reduces Stroma-Based pSTAT5Y694 in FLT3-ITD+ AML and Overcomes FLT3 TKI Resistance Blood. 132: 2641-2641. DOI: 10.1182/Blood-2018-99-117276 |
0.435 |
|
| 2017 |
Wallace JA, Kagele DA, Eiring AM, Kim CN, Hu R, Runtsch MC, Alexander M, Huffaker TB, Lee SH, Patel AB, Mosbruger TL, Voth W, Rao DS, Miles RR, Round JL, et al. miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response. Blood. PMID 28432220 DOI: 10.1182/Blood-2016-09-740209 |
0.451 |
|
| 2017 |
Than H, Pomicter AD, Mason CC, Eiring AM, Heaton WL, Yan D, Senina A, Clair PM, Holyoake TL, O'Hare T, Deininger MW. Inhibition of Nucleocytoplasmic Export Enhances Selective Elimination of Leukemic Stem Cells in Chronic Myeloid Leukemia Blood. 130: 42-42. DOI: 10.1182/Blood.V130.Suppl_1.42.42 |
0.525 |
|
| 2016 |
Khorashad JS, Tantravahi SK, Yan D, Mason CC, Qiao Y, Eiring AM, Gligorich K, Hein T, Pomicter AD, Reid AG, Kelley TW, Marth GT, O'Hare T, Deininger MW. Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy. Leukemia. PMID 27480386 DOI: 10.1038/Leu.2016.218 |
0.313 |
|
| 2016 |
Wagle M, Eiring AM, Wongchenko M, Lu S, Guan Y, Wang Y, Lackner M, Amler L, Hampton G, Deininger MW, O'Hare T, Yan Y. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Leukemia. PMID 27044711 DOI: 10.1038/Leu.2016.51 |
0.468 |
|
| 2016 |
Ali AM, Gómez-Biagi RF, Rosa DA, Lai PS, Heaton WL, Park JS, Eiring AM, Vellore NA, de Araujo ED, Ball DP, Shouksmith AE, Patel AB, Deininger MW, O'Hare T, Gunning PT. Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. Chemmedchem. PMID 27028877 DOI: 10.1002/Cmdc.201600021 |
0.478 |
|
| 2016 |
Eiring AM, Khorashad JS, Agarwal A, Mason CC, Bell R, Senina A, Pomicter AD, Yu F, Redwine HM, Bowler AD, Clair PM, Tantravahi SK, McWeeney SK, Druker BJ, Stirewalt DL, et al. MS4A3: A New Player in Leukemic Stem Cell Survival in Chronic Myeloid Leukemia Blood. 128: 934-934. DOI: 10.1182/Blood.V128.22.934.934 |
0.491 |
|
| 2016 |
Yan D, Tantravahi SK, Pomicter AD, Senina A, Gantz KC, Redwine HM, Prchal JT, Swierczek S, Clair PM, Eiring AM, Baloglu E, O'Hare T, Deininger MW. Selective Inhibition of Nuclear Cytoplasmic Transport As a New Treatment Paradigm in Myelofibrosis Blood. 128: 636-636. DOI: 10.1182/Blood.V128.22.636.636 |
0.449 |
|
| 2016 |
Patel A, Pomicter AD, Eiring AM, Hein T, Heaton WL, O'Hare T, Deininger MW. Stroma-Based Activation of pSTAT3Y705 Confers Resistance to FLT3 Inhibitors in FLT3 ITD-Positive AML Blood. 128: 34-34. DOI: 10.1182/Blood.V128.22.34.34 |
0.463 |
|
| 2016 |
Ali AM, Gómez-Biagi RF, Rosa DA, Lai P, Heaton WL, Park JS, Eiring AM, Vellore NA, de Araujo ED, Ball DP, Shouksmith AE, Patel AB, Deininger MW, O'Hare T, Gunning PT. Inside Cover: Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities (ChemMedChem 8/2016) Chemmedchem. 11: 731-731. DOI: 10.1002/Cmdc.201600185 |
0.367 |
|
| 2015 |
Eiring AM, Khorashad JS, Anderson DJ, Yu F, Redwine HM, Mason CC, Reynolds KR, Clair PM, Gantz KC, Zhang TY, Pomicter AD, Kraft IL, Bowler AD, Johnson K, Partlin MM, et al. β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia. PMID 26202934 DOI: 10.1038/Leu.2015.196 |
0.412 |
|
| 2015 |
Pomicter AD, Eiring AM, Senina AV, Zabriskie MS, Marvin JE, Prchal JT, O'Hare T, Deininger MW. Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. Experimental Hematology. 43: 537-45.e1-11. PMID 25912019 DOI: 10.1016/J.Exphem.2015.03.006 |
0.44 |
|
| 2015 |
Woessner DW, Eiring AM, Bruno BJ, Zabriskie MS, Reynolds KR, Miller GD, O'Hare T, Deininger MW, Lim CS. A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia. Leukemia. PMID 25721898 DOI: 10.1038/Leu.2015.53 |
0.47 |
|
| 2015 |
Khorashad JS, Eiring AM, Mason CC, Gantz KC, Bowler AD, Redwine HM, Yu F, Kraft IL, Pomicter AD, Reynolds KR, Iovino AJ, Zabriskie MS, Heaton WL, Tantravahi SK, Kauffman M, et al. shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. Blood. 125: 1772-81. PMID 25573989 DOI: 10.1182/Blood-2014-08-588855 |
0.484 |
|
| 2015 |
Eiring AM, Page BD, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia. 29: 586-97. PMID 25134459 DOI: 10.1038/Leu.2014.245 |
0.468 |
|
| 2015 |
Khorashad JS, Tantravahi SK, Yan D, Eiring AM, Redwine HM, Bowler AD, Gantz KC, Gligorich KM, Pomicter AD, Kelley TW, O'Hare T, Deininger MW. Transition of Chronic Myeloid Leukemia to Chronic Myelomonocytic Leukemia As a Tool to Observe Development of Chronic Myelomonocytic Leukemia Blood. 126: 5223-5223. DOI: 10.1182/Blood.V126.23.5223.5223 |
0.36 |
|
| 2015 |
Eiring AM, Khorashad JS, Agarwal A, Mason CC, Yu F, Redwine HM, Bowler AD, Gantz KC, Reynolds KR, Clair PM, Anderson DJ, Tantravahi SK, McWeeney SK, Druker BJ, Stirewalt DL, et al. MS4A3 Improves Imatinib Response and Survival in BCR-ABL1 Primary TKI Resistance and in Blastic Transformation of Chronic Myeloid Leukemia Blood. 126: 14-14. DOI: 10.1182/Blood.V126.23.14.14 |
0.525 |
|
| 2014 |
Eiring AM, Deininger MW. Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia. Genome Biology. 15: 461. PMID 25316524 DOI: 10.1186/S13059-014-0461-8 |
0.407 |
|
| 2014 |
Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, ... ... Eiring AM, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 26: 428-42. PMID 25132497 DOI: 10.1016/J.Ccr.2014.07.006 |
0.364 |
|
| 2014 |
Pomicter AD, Eiring AM, Senina AV, Marvin JE, Prchal JT, O'Hare T, Deininger MW. Limited Efficacy of BMS-911543 in a Murine Model of JAK2V617F Myeloproliferative Neoplasm Blood. 124: 5572-5572. DOI: 10.1182/Blood.V124.21.5572.5572 |
0.405 |
|
| 2014 |
Heaton WL, Eiring AM, Vellore NA, Resetca D, Haftchenary S, Rosa D, Ali AM, Senina AV, Pomicter AD, Page BD, Kraft IL, Reynolds KR, Wilson DJ, Baron R, O'Hare T, et al. Design, Optimization, and Pre-Clinical Evaluation of Direct, Mechanism-Based STAT3 Inhibitors for Treating Myeloid Disorders Blood. 124: 4816-4816. DOI: 10.1182/Blood.V124.21.4816.4816 |
0.476 |
|
| 2014 |
Heaton WL, Senina AV, Pomicter AD, Marvin JE, Swierczek S, Eiring AM, Prchal JT, O'Hare T, Deininger MW. Autocrine TNF-α Signaling in Hematopoietic Stem Cells Promotes Myeloproliferative Disease Progression through Activation of TNFR2 Blood. 124: 1888-1888. DOI: 10.1182/Blood.V124.21.1888.1888 |
0.373 |
|
| 2014 |
Eiring AM, Agarwal A, Khorashad JS, Mason CC, Anderson DJ, Yu F, Redwine HM, Gantz KC, Reynolds KR, McWeeney SK, Druker BJ, O'Hare T, Deininger MW. The Tumor Suppressors, MS4A3 and G0S2, Are Downregulated in CML Cells with BCR-ABL1 Kinase-Independent Resistance Blood. 124: 1786-1786. DOI: 10.1182/Blood.V124.21.1786.1786 |
0.519 |
|
| 2013 |
Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. The Journal of Clinical Investigation. 123: 4144-57. PMID 23999433 DOI: 10.1172/Jci68951 |
0.789 |
|
| 2013 |
Carella AM, Branford S, Deininger M, Mahon FX, Saglio G, Eiring A, Khorashad J, O'Hare T, Goldman JM. What challenges remain in chronic myeloid leukemia research? Haematologica. 98: 1168-72. PMID 23904234 DOI: 10.3324/Haematol.2013.090381 |
0.314 |
|
| 2013 |
Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Research. 73: 5775-86. PMID 23887971 DOI: 10.1158/0008-5472.Can-13-1318 |
0.519 |
|
| 2013 |
Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 121: 489-98. PMID 23223358 DOI: 10.1182/Blood-2012-05-431379 |
0.311 |
|
| 2013 |
Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, et al. Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood. 121: 159-69. PMID 23100311 DOI: 10.1182/Blood-2012-05-428573 |
0.644 |
|
| 2013 |
Mason CC, Kraft IL, Reynolds KR, Pomicter AD, Eiring AM, Zabriskie MS, Iovino AJ, Heaton W, Tantravahi SK, Kauffman M, Schacham S, Chenchik A, Bonneau K, O'Hare T, Deininger MW. An Unbiased shRNA Library Screen Identifies Nucleocytoplasmic Transport As a Potential Target For Treatment Of Chronic Myeloid Leukemia Blood. 122: 2707-2707. DOI: 10.1182/Blood.V122.21.2707.2707 |
0.439 |
|
| 2012 |
O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nature Reviews. Cancer. 12: 513-26. PMID 22825216 DOI: 10.1038/Nrc3317 |
0.44 |
|
| 2012 |
Ridges S, Heaton WL, Joshi D, Choi H, Eiring A, Batchelor L, Choudhry P, Manos EJ, Sofla H, Sanati A, Welborn S, Agarwal A, Spangrude GJ, Miles RR, Cox JE, et al. Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood. 119: 5621-31. PMID 22490804 DOI: 10.1182/Blood-2011-12-398818 |
0.356 |
|
| 2012 |
Traer E, MacKenzie R, Snead J, Agarwal A, Eiring AM, O'Hare T, Druker BJ, Deininger MW. Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors Leukemia. 26: 1140-1143. PMID 22094585 DOI: 10.1038/Leu.2011.325 |
0.379 |
|
| 2012 |
Eiring AM, Kraft IL, Page BD, Anderson DJ, Gu Z, Khorashad JS, Pomicter AD, Reynolds KR, Zabriskie MS, Moriggl R, Gunning PT, O'Hare T, Deininger MW. STAT3 Inhibition Synergizes with BCR-ABL1 Inhibition to Overcome Kinase-Independent TKI Resistance in Chronic Myeloid Leukemia (CML) Blood. 120: 31-31. DOI: 10.1182/Blood.V120.21.31.31 |
0.507 |
|
| 2012 |
Gu Z, Corbin AS, O'Hare T, Eiring AM, Zhang Ty, Druker BJ, Deininger MW. Suppression of CML Progenitor but Not Stem Cells Requires Simultaneous Inhibition of KIT and BCR-ABL1. Blood. 120: 2778-2778. DOI: 10.1182/Blood.V120.21.2778.2778 |
0.502 |
|
| 2012 |
Kraft IL, Eiring AM, Page BD, Mason CC, Gu Z, Khorashad JS, Anderson DJ, Pomicter AD, Reynolds KR, Estrada J, Zabriskie MS, Gunning PT, O'Hare T, Deininger MW. Next-Generation STAT3 Inhibitors As Targeted Therapeutics in Chronic Myeloid Leukemia. Blood. 120: 2445-2445. DOI: 10.1182/Blood.V120.21.2445.2445 |
0.502 |
|
| 2012 |
O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Erratum: Pushing the limits of targeted therapy in chronic myeloid leukaemia Nature Reviews Cancer. 12: 886-886. DOI: 10.1038/Nrc3408 |
0.334 |
|
| 2011 |
Eiring AM, Khorashad JS, Morley K, Deininger MW. Advances in the treatment of chronic myeloid leukemia. Bmc Medicine. 9: 99. PMID 21867560 DOI: 10.1186/1741-7015-9-99 |
0.389 |
|
| 2011 |
Eiring AM, Kraft IL, Anderson DJ, Traer E, Yu Q, Khorashad J, O'Hare T, Deininger MW. Intrinsic and Extrinsic Survival Signals Converge on STAT3 As a Critical Mediator of BCR-ABL-Independent Tyrosine Kinase Inhibitor Resistance, Blood. 118: 3742-3742. DOI: 10.1182/Blood.V118.21.3742.3742 |
0.461 |
|
| 2011 |
Yu Q, Eiring AM, Zabriskie MS, Khorashad J, Anderson DJ, Bryant JA, Loriaux MM, Tyner JW, O'Hare T, Deininger MW. Partially or Fully BCR-ABL Independent Mechanisms of in Vitro Resistance to Ponatinib Blood. 118: 2481-2481. DOI: 10.1182/Blood.V118.21.2481.2481 |
0.426 |
|
| 2011 |
Neviani P, Harb J, Oaks J, Walker C, Santhanam R, Paisie C, Eiring A, Zhang B, Perazzona B, Ma Y, Mao C, Marcucci G, Holyoake T, Volinia S, Cortes J, et al. Abstract LB-109: BCR-ABL1 kinase activity but not its expression is dispensable for Ph+ quiescent stem cell survival which depends on the PP2A-controlled Jak2 activation and is sensitive to FTY720 treatment Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-109 |
0.789 |
|
| 2010 |
Perrotti D, Eiring AM. The new role of microRNAs in cancer. Future Oncology (London, England). 6: 1203-6. PMID 20799864 DOI: 10.2217/Fon.10.78 |
0.508 |
|
| 2010 |
Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, ... Eiring AM, et al. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 17: 333-47. PMID 20385359 DOI: 10.1016/J.Ccr.2010.03.008 |
0.624 |
|
| 2010 |
Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 140: 652-65. PMID 20211135 DOI: 10.1016/J.Cell.2010.01.007 |
0.77 |
|
| 2010 |
Neviani P, Harb JG, Oaks JJ, Walker C, Santhanam R, Paisie C, Eiring A, Zhang B, Perazzona B, Ma Y, Mao C, Marcucci G, Holyoake TL, Volinia S, Cortes JE, et al. BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment Blood. 116: 515-515. DOI: 10.1182/Blood.V116.21.515.515 |
0.788 |
|
| 2010 |
Eiring AM, Harb J, Neviani P, Oaks JJ, Liu S, Spizzo R, Schwind S, Santhanam R, Hickey C, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, et al. Abstract 1950: Suppression of RISC-independent decoy and RISC-mediated RNA-pairing activities of microRNA-328 is required for maturation-arrest and enhanced survival of blast crisis CML progenitors Cancer Research. 70: 1950-1950. DOI: 10.1158/1538-7445.Am10-1950 |
0.769 |
|
| 2009 |
Eiring AM, Harb J, Neviani P, Oaks J, Liu S, Spizzo R, Schwind S, Santhanam R, Hickey C, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner C, et al. Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors. Blood. 114: 855-855. DOI: 10.1182/Blood.V114.22.855.855 |
0.764 |
|
| 2008 |
Lunsford KE, Jayanshankar K, Eiring AM, Horne PH, Koester MA, Gao D, Bumgardner GL. Alloreactive (CD4-Independent) CD8+ T cells jeopardize long-term survival of intrahepatic islet allografts. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 8: 1113-28. PMID 18522544 DOI: 10.1111/J.1600-6143.2008.02219.X |
0.358 |
|
| 2008 |
Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M, Willis W, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood. 111: 816-28. PMID 17925491 DOI: 10.1182/Blood-2007-05-090472 |
0.785 |
|
| 2007 |
Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. The Journal of Clinical Investigation. 117: 2408-21. PMID 17717597 DOI: 10.1172/Jci31095 |
0.778 |
|
| 2007 |
Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E, Ronchetti M, Roy DC, Calabretta B, Caligiuri MA, Perrotti D. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood. 110: 994-1003. PMID 17475908 DOI: 10.1182/Blood-2007-03-078303 |
0.685 |
|
| 2007 |
Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D. Requirement of the E2F3 Transcription Factor for BCR/ABL Leukemogenesis. Blood. 110: 33-33. DOI: 10.1182/Blood.V110.11.33.33 |
0.797 |
|
| 2007 |
Eiring AM, Neviani P, Calin GA, Roy DC, Croce CM, Perrotti D. MicroRNAs Act as Decoy Molecules To Restore Granulocytic Maturation of Differentiation-Arrested BCR/ABL+ Myeloid Precursors. Blood. 110: 31-31. DOI: 10.1182/Blood.V110.11.31.31 |
0.636 |
|
| 2006 |
Lunsford KE, Horne PH, Koester MA, Eiring AM, Walker JP, Dziema HL, Bumgardner GL. Activation and maturation of alloreactive CD4-independent, CD8 cytolytic T cells. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 6: 2268-81. PMID 16889609 DOI: 10.1111/J.1600-6143.2006.01479.X |
0.375 |
|
| 2006 |
Santhanam R, Neviani P, Eiring A, Oaks J, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Marcucci G, Gambacorti C, Roy D, Caligiuri MA, Bloomfield CD, Chen C, et al. FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph1 ALL Patients. Blood. 108: 288-288. DOI: 10.1182/Blood.V108.11.288.288 |
0.788 |
|
| 2006 |
Chang J, Santhanam R, Briercheck E, Eiring A, Trotta R, Notari M, Roy D, Caligiuri MA, Perrotti D. Molecular and Pharmacologic Suppression of MAPK Activity Rescues Differentiation of BCR/ABL+ Myeloid Progenitors by Releasing C/EBPa from the Inhibitory Effect of hnRNP E2. Blood. 108: 2240-2240. DOI: 10.1182/Blood.V108.11.2240.2240 |
0.672 |
|
| 2005 |
Lunsford KE, Koester MA, Eiring AM, Horne PH, Gao D, Bumgardner GL. Targeting LFA-1 and cd154 suppresses the in vivo activation and development of cytolytic (cd4-Independent) CD8+ T cells. Journal of Immunology (Baltimore, Md. : 1950). 175: 7855-66. PMID 16339521 DOI: 10.4049/Jimmunol.175.12.7855 |
0.378 |
|
| 2005 |
Horne PH, Lunsford KE, Eiring AM, Wang Y, Gao D, Bumgardner GL. CD4+ T-cell-dependent immune damage of liver parenchymal cells is mediated by alloantibody. Transplantation. 80: 514-21. PMID 16123727 DOI: 10.1097/01.Tp.0000168342.57948.68 |
0.368 |
|
| 2004 |
Lunsford KE, Gao D, Eiring AM, Wang Y, Frankel WL, Bumgardner GL. Evidence for tissue-directed immune responses: analysis of CD4- and CD8-dependent alloimmunity. Transplantation. 78: 1125-33. PMID 15502708 DOI: 10.1097/01.Tp.0000138098.19429.99 |
0.353 |
|
| 2004 |
Gao D, Lunsford KE, Eiring AM, Bumgardner GL. Critical role for CD8 T cells in allograft acceptance induced by DST and CD40/CD154 costimulatory blockade. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 4: 1061-70. PMID 15196062 DOI: 10.1111/J.1600-6143.2004.00490.X |
0.345 |
|
| Show low-probability matches. |